Quarterly report · Q2
4564.TEDINET S100PGWR
Period2022-04-01 → 2022-09-30
Filed2022-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥515m | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥241m | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | −¥618m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | −¥949m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | −¥644m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥952m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥613m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥614m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥614m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | −¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥1.7bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥2.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥3.7bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥340m | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥705m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.3bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥517m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥468m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥25m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-3.19 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.74 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.74 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.72 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 76.3% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 29
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥111,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥111,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥188m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥507m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥507m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥48m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥8m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥8m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥111,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥382m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥515m |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥515m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥111,000 |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | −¥430m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥195m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥243m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥234m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥63m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥6m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥6m |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥111,000 |
| jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥691m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥249m |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥241m |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | −¥754m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 443
| Item | Context | Value | Unit |
|---|---|---|---|
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Material matters relating to going concern etc business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所 グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)中村 祐輔 | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)東京都目黒区 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)特定有価証券信託受託者株式会社SMBC信託銀行 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内１－３－２ | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)中鶴 修一 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)埼玉県さいたま市中央区 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)株式会社SBI証券 | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)東京都港区六本木１－６－１ | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)古川 洋一 | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)東京都品川区 | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)セントラル短資株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)東京都中央区日本橋本石町３－３－14 | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)荒川 博文 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |